Remove Blog Remove Pharmaceuticals Remove Regulations Remove Sourcing
article thumbnail

Will India’s Permanent Establishment Tax Disrupt the Global Business Service Landscape? | Blog

Everest Group

In this blog, we delve into the impact of the Permanent Establishment (PE) tax within the realm of GBS. Article 7 of the UN Model empowers the source state, like India, for instance, to levy taxes on profits linked to a PE within its borders.

article thumbnail

Decoding the Generative AI Buzz in Life Sciences | Blog

Everest Group

Despite challenges and regulations, the life sciences industry is actively exploring GAI’s possibilities. Although GAI can potentially disrupt the life sciences technology ecosystem in many significant ways, navigating the various risks and challenges that come with its implementation in this highly regulated industry will be critical.

professionals

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five Factors Transforming the Life Sciences Supply Chain and Creating IT Opportunities | Blog

Everest Group

Supply chain visibility, strategic sourcing, cold chain requirements, sustainability demands, and personalized medicine are creating opportunities in the life sciences supply chain for IT partners delivering digital solutions. Read this first part of our blog series to understand the shift that is underway.

article thumbnail

Life Sciences Supply Chain Visibility: A Strong Link in the Chain | Blog

Everest Group

Improved supply chain visibility can help global pharmaceutical and medical device suppliers overcome the many logistics challenges they face post-pandemic. Read our second blog in this series to learn more. The pharmaceutical industry experienced its largest theft in 2020 when $1.2

article thumbnail

Generative AI in Clinical Development: Unlocking Possibilities and Addressing Challenges | Blog

Everest Group

GAI can analyze data from multiple sources and generate mappings that meet SDTM standards. Pharmaceutical enterprises must be aware of the following risks and biases so they can be prepared to address them: Data quality and bias : GAI relies on the quality of training data for generating meaningful outcomes.

article thumbnail

Mastering healthcare data governance with data lineage

IBM Services

For starters, healthcare organizations constantly encounter vast (and ever-increasing) amounts of highly regulated personal data. Healthcare organizations must adhere to data privacy regulations like HIPAA and GDPR. Issues with compliance and audit conduct also arise due to these scattered data sources.

article thumbnail

12 considerations when choosing MES software

IBM Business Partners

Additionally, they enable supply chain traceability and genealogy, essential for industries facing strict regulations because they can track the movement of materials and processes throughout the smart manufacturing lifecycle. pharmaceuticals, aerospace, etc.), But for a large organization, it’s just one of many sources.